Your browser doesn't support javascript.
loading
Towards Multidrug Adaptive Therapy.
West, Jeffrey; You, Li; Zhang, Jingsong; Gatenby, Robert A; Brown, Joel S; Newton, Paul K; Anderson, Alexander R A.
Afiliación
  • West J; Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida. alexander.anderson@moffitt.org jeffrey.west@moffitt.org.
  • You L; Department of Data Science and Knowledge Engineering, Maastricht University, Maastricht, the Netherlands.
  • Zhang J; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
  • Gatenby RA; Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
  • Brown JS; Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
  • Newton PK; Cancer Biology and Evolution Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
  • Anderson ARA; Department of Aerospace & Mechanical Engineering and Mathematics, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Cancer Res ; 80(7): 1578-1589, 2020 04 01.
Article en En | MEDLINE | ID: mdl-31948939
A new ecologically inspired paradigm in cancer treatment known as "adaptive therapy" capitalizes on competitive interactions between drug-sensitive and drug-resistant subclones. The goal of adaptive therapy is to maintain a controllable stable tumor burden by allowing a significant population of treatment-sensitive cells to survive. These, in turn, suppress proliferation of the less-fit resistant populations. However, there remain several open challenges in designing adaptive therapies, particularly in extending these therapeutic concepts to multiple treatments. We present a cancer treatment case study (metastatic castrate-resistant prostate cancer) as a point of departure to illustrate three novel concepts to aid the design of multidrug adaptive therapies. First, frequency-dependent "cycles" of tumor evolution can trap tumor evolution in a periodic, controllable loop. Second, the availability and selection of treatments may limit the evolutionary "absorbing region" reachable by the tumor. Third, the velocity of evolution significantly influences the optimal timing of drug sequences. These three conceptual advances provide a path forward for multidrug adaptive therapy. SIGNIFICANCE: Driving tumor evolution into periodic, repeatable treatment cycles provides a path forward for multidrug adaptive therapy.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Antineoplásicos / Medicina de Precisión / Modelos Biológicos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Res Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Antineoplásicos / Medicina de Precisión / Modelos Biológicos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Res Año: 2020 Tipo del documento: Article